A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile. Analysts got an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback